A rationally designed nanoparticle for RNA interference therapy in B-lineage lymphoid malignancies

EBioMedicine

Volumn 1, Issue 2-3, 2014, Pages 141-155

  Uckun, Fatih M ^a,b,c   Qazi, Sanjive ^a,d   Ma, Hong ^a   Yin, Lichen ^e   Cheng, Jianjun ^e  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d GUSTAVUS ADOLPHUS COLLEGE   (United States)

^e UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Cationic polypeptides; Leukemia; Nanomedicine; Nanoparticles; Nanotechnology

Indexed keywords

CD22 ANTIGEN; NANOPARTICLE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; CLONOGENESIS; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG FORMULATION; DRUG TARGETING; EXPRESSION VECTOR; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC DISORDER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LEUKEMIA; LEUKEMIA CELL; LIGHT SCATTERING; LYMPHOMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA TRANSLATION;

EID: 84922016901     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2014.10.013     Document Type: Article

References (19)

1. Burnett, J.C., Rossi, J.J., Tiemann, K., 2011. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J. 6, 1130-1146.
2. Davis, M.E., Chen, Z., Shin, D.M., 2008. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782.
3. Davis, M.E., Zuckermann, J.E., Choi, C.H.J., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, Y.D., Ribas, A., 2010. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070.
4. D'Cruz, O.J., Uckun, F.M., 2013. Novel mAb-based therapies for leukemia. In: Uckun, F.M. (Ed.), Monoclonal Antibodies in OncologyFuture Medicine. Future Medicine Ltd., London, pp. 54-77 http://dx.doi.org/10.2217/ebo.13.218.
5. Gabrielson, N.P., Lu, H., Kim, K.H., Cheng, J.A., 2012. Cell-penetrating helical polymer for siRNA delivery to mammalian cells. Mol. Ther. 20, 1599-1609.
6. Guo, S., Huang, L., 2011. Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J. Nanomater. 1-12 (Article ID 742895).
7. Harris, A.W., Pinkert, C.A., Crawford, M., Langdon, W.Y., Brinster, R.L., Adams, J.M., 1988. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J. Exp. Med. 167, 353-371.
8. Kagoya, Y., Yoshimi, A., Kataoka, K., Nakagawa, M., Kumano, K., Arai, S., Kobayashi, H., Saito, T., Iwakura, Y., Kurokawa, M., 2014. Positive feedback between NF-?B and TNF-a promotes leukemia-initiating cell capacity. J. Clin. Invest. 124 (2), 528-542. http://dx.doi.org/10.1172/JCI68101.
9. Lu, H., Wang, J., Bai, Y., Gabrielson, G., Liu, S., Lin, Y., Cheng, J., 2011. Ionic polypeptides with unusual helical stability. Nat. Commun. 2011 (2), 206. http://dx.doi.org/10.1038/ncomms1209.
10. Ma, H., Qazi, S., Ozer, Z., Gaynon, P., Reaman, G.H., Uckun, F.M., 2012. CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 156 (1), 89-98.
11. Uckun, F.M., Yiv, S., 2012. Nanoscale small interfering RNA delivery systems for personalized cancer therapy. Int. J. Nano Stud. Technol. 1, 2.
12. Uckun, F.M., Kersey, J.H., Gajl-Peczalska, K.J., Heerema, N.A., Provisor, A.J., Haag, D., Gilchrist, G., Song, C.W., Arthur, D.C., Roloff, J., et al., 1987. Heterogeneity of cultured leukemic lymphoid progenitor cells from B cell precursor acute lymphoblastic leukemia (ALL) patients. J. Clin. Invest. 80 (3), 639-646.
13. Uckun, F.M., Goodman, P., Ma, H., Dibirdik, I., Qazi, S., 2010. CD22 Exon 12 deletion as a novel pathogenic mechanism of human B-precursor leukemia. Proc. Natl. Acad. Sci. U. S. A. 107, 16852-16857.
14. Uckun, F.M., Ma,H., Zhang, J.,Ozer, Z.,Dovat, S., Mao, C., Ishkhanian, R.,Goodman, P., Qazi, S., 2012. Serine phosphorylation by SYK is critical for nuclear localization and transcription factor function of Ikaros. Proc. Natl. Acad. Sci. U. S. A. 109 (44), 18072-18077.
15. Uckun, F.M., Qazi, S., Cely, I., Sahin, K., Shahidzadeh, A., Ozercan, I., Yin, Q., Gaynon, P., Termuhlen, A., Cheng, J., Yiv, S., 2013. Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia. Blood 121 (21), 4348-4354.
16. Yen, J., Zhang, Y., Gabrielson, N.P., Yin, L., Guan, L., Chaudhury, I., Lu, H.,Wang, F., Cheng, J., 2013. Cationic, helical polypeptide-based gene delivery for IMR-90 fibroblasts and human embryonic stem cells. Biomater. Sci. 1, 719-727.
17. Yin, L., Song, Z., Qu, Q., Kim, K.H., Zheng, N., Yao, C., Chaudhury, I., Tang, H., Gabrielson, N.P., Uckun, F.M., Cheng, J., 2013a. Supramolecular self-assembled nanoparticlesmediate oral delivery of therapeutic TNF-a siRNA against systemic inflammation. Angew. Chem. Int. Ed. Engl. 52 (22), 5757-5761 (27).
18. Yin, L., Song, Z., Kim, K.H., Zheng, N., Tang, H., Lu, H., Gabrielson, N., Cheng, J., 2013b. Reconfiguring the architectures of cationic helical polypeptides to control non-viral gene delivery. Biomaterials 2013 (34), 2340-2349.
19. Zhang, Y., Lu, H., Lin, Y., Cheng, J., 2011. Water-soluble polypeptides with elongated, charged side chains adopt ultra-stable helical conformations. Macromolecules 44, 6641-6644.